Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. - Vanderijst L; Hever F; Buot A; Dauré C; Benoit J; Hanak C; Veeser J; Morgiève M; Campanella S; Kornreich C; Mallet L; Leys C; et al. (2024)

Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2024)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD - Massachusetts General Hospital (ClinicalTrials.gov, 2024)

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey. - Plourde L; Chang SL; Farzin H; Gagnon P; Hébert J; Foxman R; Deschamps P; Provost F; Masse-Grenier M; Stephan JF; Cheung K; Joly Y; et al. (2024)

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. - Szigeti B; Weiss B; Rosas FE; Erritzoe D; Nutt D; Carhart-Harris R. (2024)

Psilocybin biphasically modulates cortical and behavioral activity in mice - Brockett AT; Francis NA. (bioRxiv, 2024)

Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions. - Modlin NL; Creed M; Sarang M; Maggio C; Rucker JJ; Williamson V. (2024)

Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action - Imperial College London (ClinicalTrials.gov, 2024)

Older adults in psychedelic-assisted therapy trials: A systematic review. - Bouchet L; Sager Z; Yrondi A; Nigam KB; Anderson BT; Ross S; Petridis PD; Beaussant Y. (2024)

Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder. - Ghofrani-Jahromi Z; Nouri-Darehno S; Rahimi-Danesh M; Talaee N; Jasemi E; Razmi A; Vaseghi S. (2024)

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. - Wong S; Kwan ATH; Teopiz KM; Le GH; Meshkat S; Ho R; d'Andrea G; Cao B; Di Vincenzo JD; Rosenblat JD; McIntyre RS. (2024)

High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin. - Braun D; Rosenberg AM; Rabaniam E; Haruvi R; Malamud D; Barbara R; Aiznkot T; Levavi-Sivan B; Kawashima T. (2024)

Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review. - Lo DF; Zia H; Rajkumar P; Thakur A; O'Donnell H. (2024)

Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention. - Hovmand OR; Ebbesen Jensen M; Søgaard Juul T; Korsbak Madsen M; MacDonald Fisher P; Siggaard Stenbæk D. (2024)

MicroRNAs underlying the antidepressant effect of psilocybin - Establishing an nCounter pipeline for microRNA-quantification in the pig brain - Kaadt E; Søkilde R; Hansen H; Raval N; Lundgaard L; Just J; Knudsen G; Elfving B. (Research Square, 2024)

Synthetic surprise as the foundation of the psychedelic experience. - De Filippo R; Schmitz D. (2024)

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. - Rouaud A; Calder AE; Hasler G. (2024)

Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study - Swanson L; Jungers S; Varghese R; Cullen KR; Evans MD; Nielson J; Schallmo M. (PsyArXiv, 2024)

Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study (PsyArXiv, 2024)

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects. - E-Wen McCulloch D; Liechti ME; Kuypers KP; Nutt D; Lundberg J; Stenbæk DS; Goodwin GM; Gründer G; Butlen-Ducuing F; Haberkamp M; Thirstrup S; Knudsen GM. (2024)

Do the therapeutic effects of psilocybin involve actions in the gut? - Reed F; Foldi CJ. (2024)

Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? - Sekssaoui M; Bockaert J; Marin P; Bécamel C. (2024)

Rapid-acting antidepressant drugs modulate affective bias in rats. - Hinchcliffe JK; Stuart SA; Wood CM; Bartlett J; Kamenish K; Arban R; Thomas CW; Selimbeyoglu A; Hurley S; Hengerer B; Gilmour G; Robinson ESJ. (2024)

Aesthetic chills mitigate maladaptive cognition in depression. - Schoeller F; Jain A; Adrien V; Maes P; Reggente N. (2024)

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. - Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Kichuk SA; Martins B; et al. (2024)

Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster. - Bradshaw AJ; Ramírez-Cruz V; Awan AR; Furci G; Guzmán-Dávalos L; Dentinger BTM. (2024)

In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. - Jones NT; Wagner L; Hahn MCP; Scarlett CO; Wenthur CJ. (2024)

Psychedelic-like Activity of Norpsilocin Analogues. - Sherwood AM; Burkhartzmeyer EK; Williamson SE; Baumann MH; Glatfelter GC. (2024)

Psilocybin Promotes Cell-Type-Specific Changes in the Orbitofrontal Cortex Revealed by Single-Nucleus RNA-seq - Huang Z; Wei X; Wang Y; Tian J; Dong J; Liang B; Lu L; Zhang W. (bioRxiv, 2024)

Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin. - Stoliker D; Novelli L; Vollenweider FX; Egan GF; Preller KH; Razi A. (2024)

Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder - Johns Hopkins University (ClinicalTrials.gov, 2024)

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review - Shore R; Dobson K; Thomson N; Barnim N; Bergman H; Rideout K; McKeown S; Olmstead MC; Goldie C; Dumont E. (bioRxiv, 2024)

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial - Vanderijst L; Hever F; Buot A; Dauré C; Benoit J; Hanak C; Veeser J; Morgiève M; Campanella S; Kornreich C; Mallet L; Leys C; et al. (Research Square, 2024)

Effect of a single psilocybin treatment on Fos protein expression in male rat brain. - Funk D; Araujo J; Slassi M; Lanthier J; Atkinson J; Feng D; Lau W; Lê A; Higgins GA. (2024)

Pharmacological characterization of psilocin affinity towards different 5-HT receptors and receptor regulation after psilocybin administration in pigs - Kolesnik E.; Navarro M. López; Raval N.R.; Ozenne B.; Hansen H.D. (Neuroscience Applied, 2023)

Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. - Gukasyan N; Narayan SK (Journal of psychoactive drugs, 2023)

Potential Benefits of Psilocybin for Lupus Pain: A Case Report. - Gonzales SAB; Alexopoulos C; Arkfeld DG. (2023)

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. - Jacobs E; Murphy-Beiner A; Rouiller I; Nutt D; Spriggs MJ (Neuroethics, 2023)

Psilocybin and Other Classic Psychedelics in Depression. - Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D. (2023)

Psychedelia: The interplay of music and psychedelics. - Jerotic K; Vuust P; Kringelbach ML (Annals of the New York Academy of Sciences, 2023)

IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. - Yaden DB; Berghella AP; Hendricks PS; Yaden ME; Levine M; Rohde JS; Nayak S; Johnson MW; Garcia-Romeu A (Pharmacological research, 2023)

Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom. - Simonsson O; Hendricks PS; Stenfors CU; Goldberg SB; Honk L; Osika W (Journal of psychopharmacology (Oxford, England), 2023)

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy. - O'Donnell KC; Anderson BT; Barrett FS; Bogenschutz MP; Grob CS; Hendricks PS; Kelmendi B; Nayak SM; Nicholas CR; Paleos CA; Stauffer CS; Gukasyan N. (2023)

Is Poorly Assisted Psilocybin Treatment an Increasing Risk? - Schenberg EE; King F; da Fonseca JE; Roseman L. (2023)

Psilocybin Without Psychotherapy: A Cart Without a Horse? - Earleywine M; De Leo J; Bhayana D; Rajanna B; Scott K. (2023)

Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary. - Goodwin GM; Malievskaia E; Fonzo GA; Nemeroff CB. (2023)

The safety of supported psilocybin use in Oregon. - Smith WR; Sisti DA; Appelbaum PS. (2023)

CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. - Madsen MK; Petersen AS; Stenbaek DS; Sørensen IM; Schiønning H; Fjeld T; Nykjaer CH; Larsen SMU; Grzywacz M; Mathiesen T; Klausen IL; Overgaard-Hansen O; et al. (2023)

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. - Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; et al. (2023)

Valuing the Acute Subjective Experience. - Cheung K; Earp BD; Yaden DB. (2023)

[Up-to-Date on clinical and preclinical studies of psilocybin therapy]. - Ibi D. (2023)

Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD). - Olivier B; Olivier JDA. (2023)

Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders. - Martire G; Sipple D; Baron D; Gold MS; Lewandowski KU; Dennen CA; Sharafshah A; Elman I; Thanos PK; Modestino EJ; Badgaiyan RD; Pinhasov A; et al. (Journal of addiction psychiatry, 2023)

Keeping the promise: a critique of the current state of microdosing research. - Petranker R; Anderson T; Fewster EC; Aberman Y; Hazan M; Gaffrey M; Seli P (Frontiers in psychiatry, 2023)

Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey. - Glynos NG; Aday JS; Kruger D; Boehnke KF; Lake S; Lucas P (Frontiers in psychiatry, 2023)

Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics. - Thomas KL; Jesse R; Mehtani NJ; Mitchell JM; Anderson BT (Journal of psychoactive drugs, 2023)

Attitudes of European psychiatrists on psychedelics: a qualitative study. - Žuljević MF; Breški N; Kaliterna M; Hren D (Frontiers in psychiatry, 2023)

[The nursing role in psychedelic-assisted psychotherapy]. - Amberger C; Szczesniak L (Revue de l'infirmiere, 2023)

Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals. - Armand S; Larsen K; Madsen MK; Ozenne B; Preller KH; Knudsen GM; Stenbæk DS; Fisher PM. (2023)

Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis. - Danias G; Appel J. (2023)

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression - Poulin JM; Bigford GE; Lanctot KL; Giacobbe P; Schaffer A; Sinyor M; Rabin JS; Masellis M; Singnurkar A; Pople CB; Lipsman N; MacIntosh BJ; et al. (Research Square, 2023)

Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J mice. - Fletcher PJ; Li Z; Ji XD; Lê AD. (2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS. (PsyArXiv, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS. (PsyArXiv, 2023)

Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma. - Multidisciplinary Association for Psychedelic Studies (ClinicalTrials.gov, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview (PsyArXiv, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin (PsyArXiv, 2023)

Potential use of psilocybin drugs in the treatment of depression. - Śladowska K; Kawalec P; Brzostek T; Pilc A. (2023)

Molecular and Medical Aspects of Psychedelics. - Wojtas A; Gołembiowska K. (2023)

Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS). - Gomonit MM; Skillman B; Swortwood MJ. (2023)

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial. - Falchi-Carvalho M; Wießner I; Silva SRB; O Maia L; Barros H; Laborde S; Arichelle F; Tullman S; Silva-Costa N; Assunção A; Almeida R; Pantrigo ÉJ; et al. (2023)

Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study. - Wojtas A; Bysiek A; Wawrzczak-Bargiela A; Maćkowiak M; Gołembiowska K. (2023)

Is there credible evidence to assert psilocybin-assisted therapy for depression? - Nogueira GN; Vasconcelos MMA; Souza FGM; Bisol LW. (2023)

Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. - Shah FI; Shehzadi S; Akram F; Haq IU; Javed B; Sabir S; Kazim Y; Ashfaq S. (2023)

Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin. - Steward T. (2023)

Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry. - Goff R; Smith M; Islam S; Sisley S; Ferguson J; Kuzdzal S; Badal S; Kumar AB; Sreenivasan U; Schug KA. (2023)

Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. - Beaussant Y; Tarbi E; Nigam K; Miner S; Sager Z; Sanders JJ; Ljuslin M; Guérin B; Thambi P; Tulsky JA; Agrawal M. (2023)

Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer. - Thrul J; Kozak Z; Carducci MA; Garcia-Romeu A; Yaden DB. (2023)

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. - Agrawal M; Richards W; Beaussant Y; Shnayder S; Ameli R; Roddy K; Stevens N; Richards B; Schor N; Honstein H; Jenkins B; Bates M; et al. (2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders - Yale University (ClinicalTrials.gov, 2023)

Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue. - Robinson GI; Li D; Wang B; Rahman T; Gerasymchuk M; Hudson D; Kovalchuk O; Kovalchuk I. (2023)

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms. - McCulloch DE; Lopez JP; Dalla C; Castrén E; Erritzoe D; Frokjaer VG; Lundberg J; Preller KH; Fisher PM; Knudsen GM. (2023)

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats. - Reinwald JR; Schmitz CN; Skorodumov I; Kuchar M; Weber-Fahr W; Spanagel R; Meinhardt MW. (2023)

Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms - Conn K; Milton L; Huang K; Munguba H; Ruuska J; Lemus M; Greaves E; Homman-Ludiye J; Oldfield B; Foldi C. (bioRxiv, 2023)

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers. - Mathai DS; Hilbert S; Sepeda ND; Strickland JC; Griffiths RR; Garcia-Romeu A. (2023)

Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development. - Weintraub MJ; Jeffrey JK; Grob CS; Ichinose MC; Bergman RL; Cooper ZD; Miklowitz DJ. (2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions. - Brennan W; Kelman AR; Belser AB. (2023)

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. - Nicholas CR; Horton DM; Malicki J; Baltes A; Hutson PR; Brown RT. (2023)

CHIẾT XUẤT PSILOCIN TỪ NẤM THỨC THẦN LÀM NGUYÊN LIỆU THIẾT LẬP CHUẨN - Trần Nguyên Hà; Đặng Đức Khanh; Phạm Đức Trọng; Nguyễn Xuân Trường (Tạp chí Y học Quân sự, 2023)

The effect of casing and gypsum on the yield and psychoactive tryptamine content of Psilocybe cubensis (Earle) Singer. - Foster K; Morrison I; Tyler M; Delgoda R. (2023)

Statistical diversity distinguishes global states of consciousness - Starkey J; Carhart-Harris RL; Pigorini A; Nobili L; Barrett AB. (bioRxiv, 2023)

Group psychedelic therapy: empirical estimates of cost-savings and improved access. - Marseille E; Stauffer CS; Agrawal M; Thambi P; Roddy K; Mithoefer M; Bertozzi SM; Kahn JG. (2023)

Preclinical models of treatment-resistant depression: challenges and perspectives. - Kolasa M; Faron-Górecka A (Pharmacological reports: PR, 2023)

Psilocybin therapy to reduce depression following a terminal diagnosis. - Boudreau E; Orlowski K. (2023)

Psilocybin's Erasure of EGO. - Ahlskog G. (2023)

Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations. - McTaggart AR; McLaughlin S; Slot JC; McKernan K; Appleyard C; Bartlett TL; Weinert M; Barlow C; Warne LN; Shuey LS; Drenth A; James TY. (2023)

Development and validation of a sensitive LC-MS-MS method to quantify psilocin in authentic oral fluid samples. - Cardoso MS; da Cunha KF; Silva IG; Fiorentin TR; de Campos EG; Costa JL. (2023)

Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain. - Kolbman N; Liu T; Guzzo P; Gilligan J; Mashour GA; Vanini G; Pal D. (2023)

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. - Duan W; Cao D; Wang S; Cheng J. (2023)

Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. - Wang SM; Kim S; Choi WS; Lim HK; Woo YS; Pae CU; Bahk WM. (2023)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD). - Apex Labs Ltd. (ClinicalTrials.gov, 2023)

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds. - Waldbillig A; Baranova M; Neumann S; Andrade J; Sidhu S. (2023)

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (2023)

[Feeling unwell after eating a piece of chocolate]. - van der Schuur-Saleem R; Visser E; Robben H; Zwols M; den Besten-Berthololee D. (2023)

A Brief Historical Overview of Psychedelic Research. - Geyer MA. (2023)

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach - McAlpine R; Krajnović K; Khan M; Morometescu L; Simonsson O; Sacchet M; Kamboj S. (PsyArXiv, 2023)

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach (PsyArXiv, 2023)

Biological studies of clavine alkaloids targeting CNS receptors. - Tasker NR; Pazur EJ; Wipf P. (2023)

Drug-drug interactions involving classic psychedelics: A systematic review. - Halman A; Kong G; Sarris J; Perkins D. (2023)

Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders. - Raithatha SA; Hagel JM; Matinkhoo K; Yu L; Press D; Cook SG; Sharma G; Dhananjaya D; Jensen G; Lee JB; Cai C; Gallant J; et al. (2023)

Wood-loving magic mushrooms from Australia are saprotrophic invaders in the northern hemisphere - McTaggart A; Scarlett K; Slot J; Barlow C; Appleyard C; Gardiner D; Fechner N; Tilden J; Hass D; Voogelbreinder S; Lording W; Lloyd R; et al. (Authorea Preprints, 2023)

Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. - Hovmand OR; Poulsen ED; Arnfred S. (2023)

Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. - Hernandez-Leon A; Escamilla-Orozco RI; Tabal-Robles AR; Martínez-Vargas D; Romero-Bautista L; Escamilla-Soto G; González-Romero OS; Torres-Valencia M; González-Trujano ME. (2023)

Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. - Bahji A; Lunsky I; Gutierrez G; Vazquez G. (2023)

Aesthetic Chills Mitigate Maladaptive Cognition In Depression - Schoeller F; Jain A; Adrien V; Maes P; Reggente N. (Research Square, 2023)

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. - Kvam TM; Uthaug MV; Andersen KAA; Refsum BB; Tunstad PA; Stewart LH; Jacobsen HB; Grønnerød C. (2023)

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential. - Raj P; Rauniyar S; Sapkale B. (2023)

The psychedelic effects of cannabis: A review of the literature. - Wolinsky D; Barrett FS; Vandrey R. (2023)

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2023)

The entropic heart: Tracking the psychedelic state via heart rate dynamics - Rosas FE; Mediano PA; Timmermann C; Luppi AI; Candia-Rivera D; Abbasi-Asl R; Gazzaley A; Kringelbach ML; Muthukumaraswamy S; Bor D; Garfinkel S; Carhart-Harris RL. (bioRxiv, 2023)

Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. - Heresco-Levy U; Lerer B. (2023)

Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. - Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A. (2023)

The possible place for psychedelics in pharmacotherapy of mental disorders. - Wojtas A. (2023)

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. - Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ. (2023)

Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney's lesions. - Iorgu AM; Vasilescu AN; Pfeiffer N; Spanagel R; Mallien AS; Inta D; Gass P. (2023)

LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain. - Van Der Walt J; Parker R. (2023)

Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports. - Žuljević MF; Mijatović A; Marušić SL; Kudrjavets G; Buljan I; Hren D. (2023)

A "Magic Mushroom" Multi-Product Sesquiterpene Synthase. - Schäfer E; Seibold PS; Bartram S; Trottmann F; Haensch VG; Gressler M; Chadeayne AR; Hertweck C; O'Connor SE; Hoffmeister D (Chembiochem: a European journal of chemical biology, 2023)

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. - Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST. (2023)

Cultivation, chemistry, and genome of Psilocybe zapotecorum - Miller DR; Jacobs JT; Rockefeller A; Singer H; Bollinger IM; Conway J; Slot JC; Cliffel DE. (bioRxiv, 2023)

The remarkable reimagining of psilocybin. - Filer CN. (2023)

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception - Muller S; Cavanna F; de la Fuente L; Bruno N; D’Amelio TA; Pallavicini C; Tagliazucchi E. (bioRxiv, 2023)

[Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland]. - Olafsson RP; Kvaran K; Ketilsdottir K; Hallgrimsdottir K; Sigurdsson EL; Sigurdsson E. (2023)

[Determination of amanita peptide and tryptamine toxins in wild mushrooms by high performance liquid chromatography-tandem mass spectrometry]. - Liu LQ; Chen JZ; Fu WS; Tang CY. (2023)

Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury. - Gray JC; Murphy M; Carter SE; Johnson MW; Wolfgang AS; Roy MJ; Maples-Keller JL. (2023)

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action. - Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A. (2023)

The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. - Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME. (2023)

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. - Kaminski D; Reinert JP. (2023)

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues - Kratina S; Lo C; Schwartz R; Strike C; Jopling S; Nayfeh A; Rush B. (PsyArXiv, 2023)

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues (PsyArXiv, 2023)

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice. - Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maeda K; González-Maeso J; Kitagaki S; et al. (2023)

Cardiovascular safety of psychedelic medicine: current status and future directions. - Wsół A. (2023)

Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms - Rakoczy RJ; Runge GN; Sen AK; Sandoval O; Nguyen Q; Roberts BR; Sciortino JH; Gibbons WJ; Friedberg LM; Andrew Jones J; McMurray MS. (bioRxiv, 2023)

Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test. - Rahbarnia A; Li Z; Fletcher PJ. (2023)

Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats. - Malikowska-Racia N; Koniewski M; Golebiowska J; Popik P. (2023)

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review. - Watford T; Masood N. (2023)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use - Mathai DS; Roberts DE; Nayak SM; Sepeda ND; Lehrner A; Johnson M; Lowe MX; Jackson H; Garcia-Romeu A. (PsyArXiv, 2023)

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. - Rieser NM; Gubser LP; Moujaes F; Duerler P; Lewis CR; Michels L; Vollenweider FX; Preller KH. (2023)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use (PsyArXiv, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II - Yale University (ClinicalTrials.gov, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I - Yale University (ClinicalTrials.gov, 2023)

Novel treatments for anorexia nervosa: Insights from neuroplasticity research. - Keeler JL; Kan C; Treasure J; Himmerich H. (2023)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study - Enriquez-Geppert S; Krc J; O'Higgins F; Lietz MP. (PsyArXiv, 2023)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study (PsyArXiv, 2023)

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. - Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD. (2023)

Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use. - Card KG; Grewal A; Closson K; Martin G; Baracaldo L; Allison S; Kruger DJ; Walsh Z. (2023)

Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology - Shinozuka K; Jerotic K; Mediano P; Zhao AT; Preller KH; Carhart-Harris R; Kringelbach ML. (bioRxiv, 2023)

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). - Donegan CJ; Daldegan-Bueno D; Sumner R; Menkes D; Evans W; Hoeh N; Sundram F; Reynolds L; Ponton R; Cavadino A; Smith T; Roop P; et al. (2023)

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. - Ko K; Carter B; Cleare AJ; Rucker JJ. (2023)

Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results. - Linguiti S; Vogel JW; Sydnor VJ; Pines A; Wellman N; Basbaum A; Eickhoff CR; Eickhoff SB; Edwards RR; Larsen B; McKinstry-Wu A; Scott JC; et al. (2023)

Psilocybin kann offenbar Depressionen lindern. - Müller T. (2023)

CROSS-SPECIES EVIDENCE FOR PSILOCIN-INDUCED VISUAL HALLUCINATIONS: RATS PERCEIVE QUALITATIVELY SIMILAR CHANGES AS HUMANS - Vejmola Cestmir; Syrová Kateřina; Šíchová Klára; Koudelka Vlastimil; Hubený Jan; Kluckova Tereza; Nikolic Marek; Kelemen Eduard; Páleníček Tomáš (IBRO Neuroscience Reports, 2023)

Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis. - Gold ND; Mallard AJ; Hermann JC; Zeifman RJ; Pagni BA; Bogenschutz MP; Ross S (Journal of palliative medicine, 2023)

Use of Psychedelics for Pain: A Scoping Review. - Goel A; Rai Y; Sivadas S; Diep C; Clarke H; Shanthanna H; Ladha KS. (2023)

Neuroimaging in psychedelic drug development: past, present, and future. - Wall MB; Harding R; Zafar R; Rabiner EA; Nutt DJ; Erritzoe D. (2023)

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence - University of New Mexico (ClinicalTrials.gov, 2023)

A suite of engineered mice for interrogating psychedelic drug actions - Chiu Y; Deutch AY; Wang W; Schmitz GP; Huang KL; Kocak DD; Llorach P; Bowyer K; Liu B; Sciaky N; Hua K; Chen C; et al. (bioRxiv, 2023)

Perceptions of psychedelic-assisted therapy among Black Americans. - Carter S; Packard G; Coghlan C; George JR; Brown AJ; Ching THW; Julian J; Maples-Keller JL. (2023)

Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala. - Kelly TJ; Bonniwell EM; Mu L; Liu X; Hu Y; Friedman V; Yu H; Su W; McCorvy JD; Liu QS. (2023)

Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study - Wojtas A; Bysiek A; Wawrzczak-Bargiela A; Maćkowiak M; Gołembiowska K. (Preprints.org, 2023)

Psychedelic 5-HT2A receptor agonism: neuronal signatures and altered neurovascular coupling. - Padawer-Curry JA; Krentzman OJ; Kuo C; Wang X; Bice AR; Nicol GE; Snyder AZ; Siegel JS; McCall JG; Bauer AQ. (bioRxiv, 2023)

Manic episode following psilocybin use in a man with bipolar II disorder: a case report. - Halim HJ; Burk BG; Fargason RE; Birur B. (2023)

Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators - Milan Scheidegger (ClinicalTrials.gov, 2023)

Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder - University of Zurich (ClinicalTrials.gov, 2023)

Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the "high-risk" addiction patient. - Black T. (2023)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. - Nayak SM; Jackson H; Sepeda ND; Mathai DS; So S; Yaffe A; Zaki H; Brasher TJ; Lowe MX; Jolly DRP; Barrett FS; Griffiths RR; et al. (2023)

Dynamic Functional Hyperconnectivity after Psilocybin Intake is Primarily Associated with Oceanic Boundlessness - Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A. (bioRxiv, 2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. - Heinzerling KG; Sergi K; Linton M; Rich R; Youssef B; Bentancourt I; Bramen J; Siddarth P; Schwartzberg L; Kelly DF. (2023)

The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors. - Tyagi R; Saraf TS; Canal CE. (2023)

Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential. - Kargbo RB. (2023)

Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions - Lobe Sciences Ltd. (ClinicalTrials.gov, 2023)

Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin. - Bhuiya NMA; Jacobs RJ; Wang K; Sun Y; Nava B; Sampiere L; Yerubandi A; Caballero J. (2023)

Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter? - Pagán AF; Lex C; Soares JC; Meyer TD. (2023)

Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations. - Wolfgang AS; Hoge CW. (2023)

Rapid, biochemical tagging of cellular activity history in vivo - Zhang R; Anguiano M; Aarrestad IK; Lin S; Chandra J; Vadde SS; Olson DE; Kim CK. (bioRxiv, 2023)

The zebrafish for preclinical psilocybin research. - Syed OA; Tsang B; Gerlai R. (2023)

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. - Mason NL; Szabo A; Kuypers KPC; Mallaroni PA; de la Torre Fornell R; Reckweg JT; Tse DHY; Hutten NRPW; Feilding A; Ramaekers JG. (2023)

P05-02: Assessment of the CYP450 inhibitory activity of psilocybin, psilocin, LSD, 5-MeO-DMT and mescaline: An in vitro study - Costa A.M.; Silva-Carvalho M.; Madureira-Carvalho A.; Dinis-Oliveira R.J.; Dias-da-Silva D. (Toxicology Letters, 2023)

Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. - Garakani A; Alexander JL; Sumner CR; Pine JH; Gross LS; Raison CL; Aaronson ST; Baron DA. (2023)

History of the administration of psychedelics in France. - Dubus Z; Grandgeorge E; Verroust V. (2023)

Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy. - Miller M; Rosa WE; Doerner Rinaldi A; Addicott K; Spence D; Beaussant Y (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. - Kiilerich KF; Lorenz J; Scharff MB; Speth N; Brandt TG; Czurylo J; Xiong M; Jessen NS; Casado-Sainz A; Shalgunov V; Kjaerby C; Satała G; et al. (2023)

Psychedelics for treatment resistant depression: are they game changers? - Kalfas M; Taylor RH; Tsapekos D; Young AH. (2023)

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. - Raison CL; Sanacora G; Woolley J; Heinzerling K; Dunlop BW; Brown RT; Kakar R; Hassman M; Trivedi RP; Robison R; Gukasyan N; Nayak SM; et al. (2023)

Psilocybin for anorexia nervosa: If it helps, let's learn how. - Attia E; Steinglass JE. (2023)

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. - Herrmann Z; Levin AW; Cole SP; Slabaugh S; Barnett B; Penn A; Jain R; Raison C; Rajanna B; Jain S (Psychedelic medicine (New Rochelle, N.Y.), 2023)

A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond. - Pepe M; Hesami M; de la Cerda KA; Perreault ML; Hsiang T; Jones AMP. (2023)

Psilocybin history, action and reaction: A narrative clinical review. - Sharma P; Nguyen QA; Matthews SJ; Carpenter E; Mathews DB; Patten CA; Hammond CJ. (2023)

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. - Kovacevich A; Weleff J; Claytor B; Barnett BS. (2023)